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Objective: This retrospective study was designed to investigate the efﬁ  cacy and tolerability 
of travoprost 0.004% substituted for latanoprost 0.005% in glaucoma patients at the Manhattan 
Veterans Administration Hospital.
Research design and methods: We conducted a chart review of patients with stable intra-
ocular pressure (IOP) undergoing a formulary change in regimen from latanoprost 0.005% to 
travoprost 0.004%. Diagnoses included primary open angle glaucoma, ocular hypertension, 
pigment dispersion glaucoma, and pseudoexfoliation glaucoma.
Main outcome measures: The primary outcome measures were IOP change between baseline 
and 6 months and patient-reported adverse events throughout the study.
Results: In the single therapy group (N = 60 eyes), the mean baseline IOP on latanoprost was 
15.8 mmHg; after 6 months on travoprost, it was 14.9 mmHg (p  0.1). In the concomitant 
therapy group (N = 126 eyes), the mean baseline IOP was 16.7 mmHg; after 6 months on 
travoprost, it was 15.9 mmHg (p  0.01). A reduction of IOP  3 mmHg occurred in 28 eyes 
of 21 patients at 6 months. An increase of IOP  3 mmHg occurred in 5 eyes of 4 patients at 
6 months. One patient was switched back to latanoprost due to irritation at 3 months. No other 
patient-reported adverse events, including increased hyperemia, were observed throughout the 
follow-up period.
Conclusions: A change in therapeutic regimen from latanoprost 0.005% to travoprost 0.004% 
maintained IOP control in stable patients, and in some produced a further reduction in IOP. 
A change in therapy from latanoprost to travoprost was effective and well-tolerated for the 
glaucoma patients in this study.
Keywords: glaucoma, intraocular pressure, prostaglandin analogue, retrospective studies, 
travoprost, latanoprost
Introduction
Prostaglandin analogues (PGAs) comprise one of the drug classes used in treating 
glaucoma. These agents act primarily by increasing uveoscleral outﬂ  ow and thereby 
lowering IOP (Crawford and Kaufman 1987; Gabelt and Kaufman 1989; Nilsson 
et al 1989; Camras 1995). Frequently, glaucoma studies that have evaluated PGA 
substitutions have been conducted on patients who were poor responders to the ﬁ  rst 
medication(s) (Williams 2002; Kaback et al 2004; Gandolﬁ   and Cimino 2003; Hollo 
et al 2005). A recent study (Law et al 2005) reported on a mass change in regimen 
(to bimatoprost) prompted by a formulary change in which patients were not poor 
responders to the original medication (latanoprost). We used the opportunity of a 
formulary change in the Veterans Administration (VA) system to review the con-
sequences of a mass change in therapeutic regimen from latanoprost to travoprost Clinical Ophthalmology 2008:2(2) 304
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in patients with adequate IOP control while on latanoprost. 
We analyzed medical records from patients in the glaucoma 
clinic at the Manhattan VA Hospital.
In July 2003, the Veterans Administration (VA) hos-
pital chose to select a single prostaglandin analogue for 
use within the system. Based on a competitive contracting 
process, the VA system elected to use travoprost as its pri-
mary PGA, and to phase out and eventually totally replace 
the use of latanoprost. All newly diagnosed glaucoma 
patients requiring a PGA were to be prescribed travoprost. 
In order to accommodate potential concerns about toler-
ability or effectiveness of changing to a new PGA, those 
patients already on latanoprost were permitted to remain 
on it at the discretion of their ophthalmologist. No industry 
support or paid recruitment for a regimen change occurred, 
however the VA strongly recommended the regimen change 
to travoprost. In August 2003, the ophthalmologists at the 
Manhattan VA hospital elected to place all stable glaucoma 
patients who were prescribed a PGA on travoprost. There 
was no direct clinical trial experience within the VA hospital 
system with travoprost. Thus, we had an interest in evaluat-
ing if travoprost would be tolerated as well and would be 
as effective as other PGAs such as latanoprost.
The purpose of this retrospective study was to evaluate 
the efﬁ  cacy and tolerability (as deﬁ  ned by changes in IOP 
and changes in adverse effects, respectively) of travoprost 
0.004% substituted for latanoprost 0.005% in a glaucoma 
population undergoing a formulary change at the VA 
hospital.
Patients and methods
We conducted a retrospective chart review of patients 
identiﬁ  ed through pharmacy records as being moved from 
latanoprost 0.005% to travoprost 0.004% from August, 
2003 through July, 2004 at the Manhattan VA Hospital. The 
study was approved by the institutional review board (IRB) 
of the New York Campus of the New York Harbor Health-
care System of the Veterans Administration. In accordance 
with minimal patient risk, a waiver of consent was obtained 
from the IRB. A computerized pharmacy dispensing 
database was accessed, and a printout of those patients 
was generated. We selected only patients with diagnoses 
of open angle glaucomas, including primary open angle 
glaucoma (POAG), pigment dispersion glaucoma (PDG), 
or pseudoexfoliation glaucoma (PSX), and ocular hyperten-
sion (OHT), who were treated in the glaucoma clinic at the 
Manhattan VA. We excluded uveitis and other disorders 
that may be associated with IOP ﬂ  uctuations unrelated to 
the medication change. Only patients considered stable 
on the previous medication were included. Patients were 
considered stable if their IOP values had been within 
their target range for at least 6 months prior to the switch, 
and the patients were not being considered for surgery or 
therapeutic modiﬁ  cation outside of the formulary change. 
Therapeutic regimens prior to the change included latano-
prost alone or in combination with other drugs (see Results 
for speciﬁ  c therapies). No changes in medical regimen, 
ocular or oral, were permitted during follow-up, other than 
the change to travoprost. No minimum IOP was required 
for inclusion in the study.
The primary selection criterion for inclusion into this 
study was the availability of documentation of patient-
reported adverse events for all visits during the study. 
We used a direct questioning survey designed to capture 
changes in adverse events. Questions drew upon subjective 
patient assessment of any changes in adverse events, such 
as hyperemia and irritation (see Appendix). At the baseline 
visit, patients were speciﬁ  cally asked if they had experienced 
any adverse events since beginning latanoprost. At all follow-
up visits, they were asked if any changes occurred after 
changing to travoprost. These responses were documented 
in the electronic record of each patient. In addition, patients 
selected for inclusion had to be seen in the VA clinic by one 
of the doctors and IOP data had to be present in the electronic 
record for all visits. It should be noted that all patients whose 
regimen was changed from latanoprost to travoprost were 
included in the survey, regardless of whether they met the 
other inclusion criteria which were formulated retrospec-
tively. This was done to ensure the inclusion of all potential 
patients for subsequent data analysis and help eliminate any 
inclusion/exclusion bias.
Intraocular pressure was measured by Goldmann 
tonometry at baseline (prior to the regimen change), at 
3 months (± 2 weeks), and at 6 months (± 2 weeks) after 
the patients received travoprost. Measurements were 
made by a total of eight to ten observers, as the study 
was performed within a residency training program. All 
measurements were performed by third-year residents with 
training administered by Dr. Farris on the proper method 
of Goldmann tonometry. The same tonometer was used for 
every patient at every visit. The tonometer was preset to 
20 mmHg prior to any measurements being performed and 
was calibrated monthly. All measurements were obtained 
between 12:30 pm and 3:00 pm. We used IOP from both 
eyes and considered each eye as an independent unit of 
measurement.Clinical Ophthalmology 2008:2(2) 305
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The primary outcome measures were IOP change 
between baseline and 6 months and patient-reported adverse 
events throughout the study.
Results
The study consisted of 188 eyes of 97 patients. All patients 
were male. Demographic data are shown in Table 1. The 
diagnoses for these patients were as follows: POAG (86%), 
OHT (6%), PSX (6%), and PDG (2%). POAG accounted for 
71% of monotherapy patients and 92% of the concomitant 
therapy group. The monotherapy group included 60 eyes 
and the concomitant therapy group 128 eyes. One patient 
(2 eyes) in the concomitant therapy group was switched back 
to latanoprost at 3 months due to irritation, and thus was not 
included in ﬁ  nal statistical analyses. Due to the small number 
of patients for whom data were available at 3 months, we 
elected to omit these data from our ﬁ  nal analysis.
In the concomitant therapy group, medications prescribed 
in addition to latanoprost included: dorzolamide/timolol in 
112 eyes (88%); brimonidine in 94 eyes (73%); timolol in 13 
eyes (10%); and pilocarpine in 4 eyes (3%). Regimen details 
are shown in Table 2.
In the single therapy group (N = 60 eyes), the mean baseline 
IOP on latanoprost was 15.8 ± 3.1 mmHg (Figure 1). After 
6 months on travoprost the mean IOP was 14.9 ± 2.5 mmHg 
(p  0.1). In the concomitant therapy group (N = 126 eyes), 
the mean baseline IOP on latanoprost and concomitant medi-
cations was 16.7 ± 2.4 mmHg (Figure 2). After 6 months on 
travoprost and the same concomitant medications, the mean 
IOP was 15.9 ± 2.2 mmHg (p  0.01). Figure 3 shows the com-
bined data for all patients (both monotherapy and concomitant 
therapy). Six months after the change in regimen, the IOP was 
reduced by approximately an additional 1 mmHg (p  0.001). 
Reductions from baseline IOP are represented in Figure 4. Both 
the monotherapy and concomitant groups showed statistically 
signiﬁ  cant reductions in IOP from the latanoprost baseline (p 
 0.001). Figures 5 and 6 are histograms showing responses 
of individual eyes in terms of decreases/increases in IOP 
(mmHg). A reduction in IOP of 3 mmHg occurred in 28 eyes 
of 21 patients at 6 months. An increase in IOP of 3 mmHg 
occurred in 5 eyes of 4 patients at 6 months. In our study it was 
slightly more likely to achieve a 3 mmHg or more additional 
reduction in the concomitant group (21 of 126 eyes) than in 
the monotherapy group (7 of 60 eyes).
As noted above, one patient (2 eyes) was switched back 
to latanoprost at 3 months due to irritation. As evaluated by 
direct questioning survey as described above (see Appen-
dix), no other patients reported changes in adverse events 
compared to the latanoprost baseline, including increased 
hyperemia, throughout the 6-month follow-up period.
Discussion
Our study incorporates several features which distinguish it 
from previous studies. First, the patients in our study were 
considered stable (with regard to IOP) on latanoprost prior 
to the change to travoprost therapy. Previous studies have 
evaluated patients deemed nonresponders or poor respond-
ers to latanoprost prior to a regimen substitution (Williams 
2002; Kaback et al 2004; Gandolﬁ   and Cimino 2003; Hollo 
et al 2005).
Second, in many glaucoma and OHT studies, sample size 
is limited by the exclusion of fellow eye results. There is 
current debate as to whether or not fellow eyes in glaucoma 
exhibit concordant IOP changes, response to treatment, 
and disease progression. Some have used fellow eyes as 
an internal control (Williams 2002). Others have observed 
independent risk factors and disease progression between 
fellow eyes (Levine et al 2006; Chen and Bhandari 2000). 
Realini and associates have observed variable fellow eye 
concordance in different studies. Observations from a 2002 
study led Realini et al to conclude that the frequency and 
magnitude of spontaneous asymmetric ﬂ  uctuations in IOP 
Table 1 Demographics and diagnoses 
Parameter
Mean age in years  65 ± 9.4
 %  of  patients
Ethnicity 
 Black  52
 Caucasian  39
 Hispanic  7
 Asian  2
Diagnosis 
  Primary open angle glaucoma  86
 Pseudoexfoliation  glaucoma  6
 Ocular  hypertension  6
  Pigment dispersion glaucoma  2
Table 2 Concomitant therapy with latanoprost
# Eyes  % Eyes 
81  63  Dorzolamide/timolol and brimonidine
29 23  Dorzolamide/timolol
6  5  Timolol and brimonidine
5 4  Timolol
3 2  Brimonidine
2  2  Dorzolamide/timolol, brimonidine, and pilocarpine
2  2  Timolol, brimonidine, and pilocarpineClinical Ophthalmology 2008:2(2) 306
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between fellow eyes in glaucoma patients could potentially 
confound the interpretation of monocular drug trials (Realini 
et al 2002). A 2004 study by Realini and colleagues concluded 
that the response of the second eye to glaucoma medication 
could not be adequately predicted from the response of the 
ﬁ  rst eye (Realini et al 2004). In contrast, a 2005 study by 
Realini and Vickers observed marked symmetry in fellow eye 
IOP response to glaucoma medications (Realini et al 2005). 
Baseline Month 6
12
14
16
18
M
e
a
n
 
I
O
P
 
(
m
m
H
g
)
Concomitant therapy
**
Figure 2 Concomitant therapy group: Patients were on latanoprost 0.005% plus concomitant therapy prior to the switch to travoprost 0.004% plus concomitant therapy. 
Six months after the switch the IOP was reduced by approximately an additional 1 mmHg (mean + SEM, **p  0.01; n = 126).
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Figure 1 Monotherapy group: Patients were on latanoprost 0.005% monotherapy prior to the switch to travoprost 0.004% monotherapy. Six months after the switch the 
IOP was reduced by approximately an additional 1 mmHg (mean + SEM, p  0.1; n = 60).Clinical Ophthalmology 2008:2(2) 307
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Figure 3 Patients were on latanoprost 0.005% monotherapy or latanoprost plus concomitant therapy prior to the switch to travoprost 0.004%. Six months after the switch 
the IOP was reduced by approximately an additional 1 mmHg (mean + SEM, **p  0.001; n = 186).
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Figure 4 Patients were on latanoprost 0.005% monotherapy or concomitant therapy prior to the switch to travoprost 0.004%. Data presented are based on the number of 
eyes with IOP measurement available from the speciﬁ  c visit. Changes = Follow-up IOP – Baseline IOP of the same eye.   A negative number indicates a reduction in IOP.   The 
results indicate that in each group, the within-eye IOP changes from pre-switch to 6 months (n = 60 monotherapy; n = 126 concomitant therapy) after switch were statistically 
signiﬁ  cant (mean + SEM, ***p  0.001, †p  0.0001).Clinical Ophthalmology 2008:2(2) 308
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Recently, Dinn et al observed that the diurnal variation of 
IOP in POAG is largely concordant between fellow eyes, 
but that fellow eye IOP may ﬂ  uctuate asymmetrically a 
minority of the time (Dinn et al 2007). In view of evidence 
for independent risk factors and conﬂ  icting observations 
regarding symmetrical response to medication, we chose to 
consider fellow eyes independently.
The methodology and results of our mass change to 
travoprost were comparable to those of Law et al (2005) in 
several ways. Both were nonrandomized analyses of a change 
from one prostaglandin analogue to another. The medica-
tion switch in both studies occurred because of a formulary 
change rather than inadequate IOP control or side effects.
Of particular interest is our observation that in our patient 
population IOP control was maintained after switching 
patients with stable IOP. Furthermore, some patients exhib-
ited a lower IOP on travoprost at the 6-month visit despite 
previous adequate control with latanoprost. An IOP decrease 
of an additional 3 mmHg or more occurred in at least one 
eye of greater than 20% of patients after switching from 
latanoprost to travoprost. In our study it was slightly more 
likely to achieve a 3 mmHg or more additional reduction in 
the concomitant (21 of 126 eyes) than in the monotherapy 
(7 of 60 eyes) group. This ﬁ  nding contrasts with the results 
observed by Law and colleagues, where most patients with 
3 mmHg additional reduction were in the monotherapy 
group. An increase in IOP  3 mmHg occurred in 5 eyes of 
4 patients, all in the concomitant therapy group. No patient 
in the monotherapy group showed an increase in IOP  3 
mmHg at 6 months. These observations may support the 
theory that individual patients will have different responses 
to the medications in the prostaglandin class. Speciﬁ  cally, 
travoprost has been shown to be a full agonist at the FP recep-
tor while latanoprost is a partial agonist (Grifﬁ  n et al 1997; 
Hellberg et al 2002; Sharif et al 2002). This difference in 
agonist activity could account for the differential responses 
seen in our study.
Another salient result in our study was that no signiﬁ  cant 
increase in side effects was observed in the 6 month period 
following the switch to travoprost. In a 12-week trial involv-
ing more than 1000 patients, Przydryga et al (2004) found 
that 8% of patients experienced conjunctival hyperemia when 
switched to travoprost. In contrast, no increase in conjunctival 
hyperemia was reported by patients at any time after the 
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Figure 5 At 6 months, a few patients previously on monotherapy experienced an increase in IOP while several experienced a decrease in IOP of 3 mmHg or more (n = 60).Clinical Ophthalmology 2008:2(2) 309
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switch to travoprost (compared to latanoprost baseline) in our 
study. One patient (2 eyes) chose to switch back to latanoprost 
due to irritation at the 3-month visit.
The Early Manifest Glaucoma Trial (EMGT) (Leske et al 
2003, 2004) suggested that each mean increase of 1 mmHg 
in IOP increases by 10% the risk of visual ﬁ  eld deterioration. 
Further studies are needed to assess the clinical relevance of 
such small incremental changes in individual patients. Our 
results include data on decreases of up to 6 mmHg after 6 
months on travoprost (see Figures 5 and 6). The change seen 
in mean IOP in both groups is statistically signiﬁ  cant, and 
may also be clinically relevant. However, we recognize that 
the most likely cause of the statistically signiﬁ  cant mean IOP 
reduction is the number of patients whose IOP was lowered 
greater than 3mmHg compared to those whose IOP rose 
greater than 3mmHg. Therefore, in our study, a change in 
regimen from latanoprost to travoprost resulted in minimal 
change in IOP for most patients; however, a signiﬁ  cant 
lowering of IOP was seen in some patients at 6 months. 
Few to none exhibited a signiﬁ  cant rise in IOP which would 
prompt a further change in regimen.
The occurrence of further IOP decreases with travoprost 
in patients who were already controlled is intriguing. Main-
tenance of control and the absence of signiﬁ  cant side effects 
(notably the absence of increased hyperemia) conferred no 
disadvantage to a substitution to travoprost in our study. In 
addition, the change in therapeutic regimen provided the 
opportunity to optimize control.
The nature of data collection subjects this study to several 
limitations. First, patients were sequentially, not randomly 
selected. However, patients selected for inclusion in the study 
are typical of those seen in clinical practice in regard to such 
factors as age, disease state, and potential for beneﬁ  ting from 
medical intervention. In addition, circumstances of the thera-
peutic substitution such as the lack of a washout phase of the 
previous medication are typical of everyday clinical practice. 
Because the study was conducted at the VA, a predominantly 
male population, no female patients were included. No data 
on gender variation of PGA response are available, however 
there is no reason to suspect that such variation exists. Thus, 
the study patients are in many ways representative of the 
population to which the results will be applied.
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Figure 6 At 6 months, a few patients previously on concomitant therapy experienced an increase in IOP while several experienced a decrease in IOP of 3 mmHg or more 
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In addition to non-randomization, the study was open-
label, thus presenting the possibility that participants were 
inﬂ  uenced toward better compliance. However, such assess-
ment bias was likely minimal because patients knew their 
medication was being substituted purely due to a change in 
formulary. In accordance with minimal patient risk, a waiver 
of consent had been obtained from the IRB, and patients 
were aware that the new medication was not required due 
to medication failure or advancing disease. Thus patient 
motivation for better compliance seems unlikely. Another 
limitation posed by our evaluation is the inclusion of mul-
tiple observers. Inter-observer differences in technique could 
account for some changes in IOP, and these potential differ-
ences are difﬁ  cult to analyze separately. However, intra- and 
inter-observer variation have been reported to range from 
less than 1 mmHg to more than 3 mmHg (Sudesh et al 
1993; Dielemans et al 1994; Kaufman et al 2004; Tonnu 
et al 2005). In addition, inter-observer differences were 
at least partially offset by the fact that all observers were 
third-year residents with similar training administered by 
Dr. Farris on the proper method of Goldmann tonometry. 
The same tonometer was used for every patient at every 
visit. The tonometer was preset to 20 mmHg prior to any 
measurements being performed and was calibrated monthly. 
Moreover, it is unlikely that most differences introduced by 
inter-observer variation would fall in the same direction and 
account for the statistically signiﬁ  cant results obtained in 
our study. A further limitation of the study was observation 
of a single IOP at all study points. Diurnal variation was 
minimized, however, by measuring all IOP within a 3-hour 
window in the afternoon. It seems unlikely that any of the 
above limitations could account for the high percentage of 
patients with a decrease in IOP versus the low percentage 
with an increase after the regimen change.
Conclusions
A large scale change in regimen from latanoprost 0.005% to 
travoprost 0.004% maintained IOP control in stable patients 
and in some produced a further reduction in IOP. Reductions 
from baseline occurred at 6 months in the monotherapy and 
concomitant groups. There were no patient-reported events 
of increased hyperemia throughout 6 months of treatment. A 
change in therapy from latanoprost to travoprost was effective 
and well-tolerated for the glaucoma patients in this study.
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Appendix
Patient Survey
Patients were asked the following questions before and 
after the change in regimen from latanoprost to travoprost. 
Answers were recorded in the patients’ medical record.
Questions at baseline:
Do you experience any stinging/burning/irritation when 
placing your latanoprost drop?
Yes/No
Have you noticed an increase in the length of eyelashes 
since beginning latanoprost?
Yes/No
Have you noticed an increase in the darkness around your 
eyes since beginning latanoprost?
Yes/No
Has there been any change in the color of your eyes since 
beginning latanoprost?
Yes/No
Have you noticed any increase in eye redness since 
beginning latanoprost?
Yes/No
Questions at follow-up:
Have you noticed any increase or decrease in stinging/burn-
ing/irritation since the switch to travoprost? Identify/None
Have you noticed any increase in eyelash length since 
the switch to travoprost?
Yes/No
Have you noticed any increase in darkness around your 
eyes since the switch to travoprost?
Yes/No
Have you noticed any change in the color of your eyes 
since the switch to travoprost?
Yes/No
Has there been any increase in eye redness since the 
switch to travoprost?
Yes/No